8-K: SBC Medical Q4 EPS Doubles, Strategic Shift Underway

SBC Medical Group Holdings Incorporated announced its fourth quarter and full year 2025 financial results, showing significant net income growth despite revenue declines due to strategic restructuring.

Summary

• Total revenues for Q4 2025 were $40 million, an 11% year-over-year decrease.
• Net Income attributable to SBC Medical Group for Q4 2025 was $14 million, representing a 117% year-over-year increase.
• Earnings per share for Q4 2025 was $0.14, a 133% year-over-year increase.
• Total revenues for the full year 2025 were $174 million, a 15% year-over-year decrease.
• Net Income attributable to SBC Medical Group for the full year 2025 was $51 million, a 9% year-over-year increase.
• Earnings per share for the full year 2025 was $0.50, a 4% year-over-year increase.
• The revenue decline was primarily due to a business restructuring in 2024 and revised franchise fee arrangements implemented in April 2025.
• Average revenue per customer recovered to $316 in Q4 2025, an 11% increase year-over-year.
• The company ended 2025 with 283 clinic locations, an increase of 34 locations from December 31, 2024.
• The number of customers in 2025 was 6.6 million, a 12% year-over-year increase, with a repeat rate of 72%.
• Updates to business strategy and capital policy were announced in connection with the financial results.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report. While revenue declined due to strategic restructuring, the significant increase in net income and EPS, coupled with positive operational metrics like customer growth and repeat rates, suggests the company is successfully navigating its transition towards improved profitability and a more sustainable business model.

Positives

• Q4 2025 Net Income attributable to SBC Medical Group increased 117% year-over-year to $14 million.
• Q4 2025 Earnings per share more than doubled to $0.14, a 133% year-over-year increase.
• Full Year 2025 Net Income attributable to SBC Medical Group grew 9% to $51 million.
• Full Year 2025 Earnings per share increased 4% to $0.50.
• Net income margin expanded from 23% to 29% for the full year, as prior-year IPO-related stock-based compensation and impairment losses did not recur.
• Average revenue per customer recovered to $316 in Q4 2025, an 11% year-over-year increase, reflecting early impact of pricing and customer engagement initiatives.
• Number of franchise locations increased by 34 to 283 as of December 31, 2025.
• Number of customers increased 12% year-over-year to 6.6 million in 2025.
• Customer repeat rate was 72% for clinics included in the calculation.
• Selected for inclusion in the Russell 3000 Index in June 2025.

Negatives

• Q4 2025 Total revenues decreased 11% year-over-year to $40 million.
• Q4 2025 EBITDA decreased 35% year-over-year to $14 million.
• Q4 2025 EBITDA margin decreased 12 percentage points year-over-year to 34%.
• Full Year 2025 Total revenues decreased 15% year-over-year to $174 million.
• Full Year 2025 EBITDA decreased 21% year-over-year to $70 million.
• Full Year 2025 EBITDA margin decreased 3 percentage points year-over-year to 40%.
• Revenue decline attributed to business restructuring in 2024 and revised franchise fee arrangements in April 2025.

Risks

• Forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify.
• Factors that may cause actual results to differ materially include changes in global, regional, or local economic, business, competitive, market, and regulatory conditions.
• Specific risk factors are listed under the heading 'Risk Factors' and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the SEC), which are accessible on the SEC's website.

Future Outlook

The company is focused on three priorities for 2026: advancing its multi-brand strategy in the dermatology segment, expanding its non-aesthetic healthcare portfolio, and building a stronger foundation in international markets. Management believes the structural headwinds of the past two years are largely behind them, positioning the company to return to sustainable top-line growth.

Management Comments

• "Our full-year 2025 results reflect a business in transition." Yoshiyuki Aikawa, Chairman and Chief Executive Officer.
• "Revenue declined 15% to $174 million, primarily due to two structural changes: the business restructuring undertaken in 2024, and the revision of franchise fee arrangements implemented in April 2025. These were deliberate steps to build a more sustainable business foundation, and their financial impact is now largely behind us." Yoshiyuki Aikawa, Chairman and Chief Executive Officer.
• "Beneath the revenue decline, our underlying profitability strengthened considerably. Full-year net income attributable to SBC Medical Group grew 9% to $51 million, with earnings per share of $0.50." Yoshiyuki Aikawa, Chairman and Chief Executive Officer.
• "Our net income margin expanded from 23% to 29%, as the IPO-related stock-based compensation and impairment losses that weighed on our prior-year results did not recur." Yoshiyuki Aikawa, Chairman and Chief Executive Officer.
• "EBITDA margin normalized modestly from 43% to 40%, which we view as a more sustainable run-rate going forward." Yoshiyuki Aikawa, Chairman and Chief Executive Officer.
• "In the fourth quarter specifically, we saw encouraging operational momentum. Average revenue per customer recovered to $316, an 11% increase year over year — a meaningful inflection after a period of gradual decline, and one that we believe reflects the early impact of our pricing and customer engagement initiatives." Yoshiyuki Aikawa, Chairman and Chief Executive Officer.
• "As we enter 2026, we are focused on three priorities: advancing our multi-brand strategy in the dermatology segment, expanding our non-aesthetic healthcare portfolio, and building a stronger foundation in international markets." Yoshiyuki Aikawa, Chairman and Chief Executive Officer.
• "With the structural headwinds of the past two years now largely behind us, we are well-positioned to return to sustainable top-line growth." Yoshiyuki Aikawa, Chairman and Chief Executive Officer.

Industry Context

StockSavvy.ai notes that SBC Medical's strategic shift towards a more sustainable business foundation, despite initial revenue declines, aligns with broader healthcare industry trends focusing on diversified service offerings and operational efficiency. The expansion into non-aesthetic healthcare and international markets indicates a move to capture wider market segments and reduce reliance on specific niches, a common strategy among growing healthcare service providers.

Comparison to Industry Standards

• SBC Medical's 72% customer repeat rate for its clinics (excluding AHH and JUN CLINIC free counseling) is a strong indicator of customer satisfaction and loyalty, potentially outperforming some competitors in the fragmented aesthetic and general healthcare franchise market.
• The increase of 34 franchise locations to 283 by December 31, 2025, demonstrates robust expansion, comparable to growth rates seen in successful franchise models like MedSpa or urgent care chains in the U.S. and Asia.
• The 12% year-over-year increase in customer count to 6.6 million suggests effective market penetration and brand recognition, which is competitive with established multi-location healthcare providers.
• The expansion of net income margin from 23% to 29% for the full year 2025, while revenue declined, indicates strong cost management and operational leverage, potentially positioning it favorably against peers facing similar market pressures.

Corporate Governance

Related Party Transactions

• Revenues, net related parties: $35,041,379 (Q4 2025) and $158,860,970 (Full Year 2025).
• Accounts receivable related parties: $27,511,730 as of December 31, 2025.
• Short-term investments related parties: $319,193 as of December 31, 2025.
• Finance lease receivables, current related parties: $12,832,355 as of December 31, 2025.
• Finance lease receivables, non-current related parties: $13,746,513 as of December 31, 2025.
• Long-term investments in MCs related parties: $17,837,293 as of December 31, 2025.
• Accounts payable related parties: $651,463 as of December 31, 2025.
• Advances from customers related parties: $5,357,221 as of December 31, 2025.
• Due to related party: $2,692,673 as of December 31, 2025.
• Borrowings from related parties: $15,000 (2025) and $5,481,787 (2024).
• Repayments to related parties: $(145,917) (2025) and $(739,414) (2024).
• Payables to related parties in connection with loan services provided: $14,219,401 (2025) and $20,524,499 (2024).

Stakeholder Impact

• Shareholders: Improved net income and EPS, along with strategic clarity, could positively impact shareholder value. Inclusion in the Russell 3000 Index may increase visibility and liquidity.
• Customers: Increased customer count and a high repeat rate suggest strong customer satisfaction and loyalty across the company's diverse medical franchise offerings.
• Franchisees: The increase in franchise locations indicates a growing network and potentially successful franchise model, benefiting existing and prospective franchisees.
• Employees: The company's focus on sustainable business foundation and growth could provide stability and future opportunities.

Next Steps

• Advance multi-brand strategy in the dermatology segment.
• Expand non-aesthetic healthcare portfolio.
• Build a stronger foundation in international markets.
• Hold a conference call on March 27, 2026, at 8:30 am Eastern Time to discuss results.
• Monitor the company's website for further information and updates.

Key Dates

Recommendation

While SBC Medical Group Holdings demonstrated strong profitability improvements with significant net income and EPS growth, the underlying revenue decline for both the quarter and full year 2025, attributed to structural changes, warrants a cautious approach. Management's assertion that "structural headwinds are largely behind us" and the focus on future growth initiatives are positive, but investors should monitor the execution of these strategies and the return to top-line growth before considering a stronger position. The current results suggest a business in transition, making a "hold" recommendation appropriate until sustained revenue recovery is evident.

Keywords

SBC Medical, Financial Results, Q4 2025, Full Year 2025, Earnings, Revenue, EPS, EBITDA, Franchise, Healthcare, Medical Services, Dermatology, Aesthetic Healthcare, Strategic Update, Nasdaq, Russell 3000